EsuberaprostAlternative Names: 314d; APS-314d; Beraprost Sodium 314d Modified Release; Beraprost-314d; BPS-314d-MR; L-314d-QID
Latest Information Update: 04 Feb 2015
At a glance
- Originator Toray
- Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Pulmonary arterial hypertension
Most Recent Events
- 30 May 2013 Phase-III clinical trials in Pulmonary arterial hypertension in USA (PO) (NCT01908699)